WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE

<p>Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old...

Full description

Bibliographic Details
Main Author: Miwako Narita, Masayoshi Masuko, Tohri Kurasaki, Toshiki Kitajima, Shoko Takenouchi, Anri Saitoh, Norihiro Watanabe, Tatsuo Furukawa, Ken Toba, Ichiro Fuse, Yoshifusa Aizawa, Manabu Kawakami, Yoshihiro Oka, Haruo Sugiyama, Masuhiro Takahashi
Format: Article
Language:English
Published: Ivyspring International Publisher 2010-01-01
Series:International Journal of Medical Sciences
Online Access:http://www.medsci.org/v07p0072.htm

Internet

http://www.medsci.org/v07p0072.htm

Similar Items